CD8A and neoplasm: To test whether this modification could reduce cachexia, we subsequently infused NT, nonselected, CD4 or CD8-enriched iC9-CD19.ζ-MC-modified T cells into Raji-EGFPluc-bearing NSG mice and observed that although nonselected and CD4-enriched iC9-CD19.ζ-MC CAR-T cells showed improved tumor control over NT T cells (Fig. 7b), these mice rapidly developed cachexia by day 7 post-CAR-T cell injection (Fig. 7c).